Page contents Key factsDecisionRelated medicine informationKey facts Invented name ToriselTorisel Active Substance Temsirolimus Therapeutic area Oncology Decision number P/262/2011 PIP number EMEA-000026-PIP02-11 Pharmaceutical form(s) Concentrate and diluent for solution for infusion Condition(s) / indication(s) Treatment of mantle cell lymphoma Route(s) of administration Intravenous use Contact for public enquiries Pfizer LimitedTel. + 44 1304646607E-mail: pip_enquiries@pfizer.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 28/10/2011DecisionP/262/2011: EMA decision of 28 October 2011 on the granting of a product specific waiver for temsirolimus (Torisel) (EMEA-000026-PIP02-11)AdoptedReference Number: EMA/846762/2011 English (EN) (138.04 KB - PDF)First published: 29/11/2011Last updated: 29/11/2011ViewRelated medicine informationToriselShare this page